Global Leading Market Research Publisher QYResearch announces the release of its latest report “Multi-Omics Service – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Multi-Omics Service market, including market size, share, demand, industry development status, and forecasts for the next few years.
Second paragraph (sample PDF request, link kept as text, no hyperlink):
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097128/multi-omics-service
Executive Summary
The global market for Multi-Omics Service was valued at US$ 564 million in 2025 and is projected to reach US$ 855 million by 2032, growing at a CAGR of 6.2%. Multi-omics service integrates data from multiple omics layers: genomics (DNA), transcriptomics (RNA), proteomics (proteins), metabolomics (metabolites), and epigenetics. It combines bioinformatics, systems biology, and big data analytics to analyze molecular mechanisms, functional networks, and dynamic changes in organisms under specific conditions. Core goals: reveal complexity of life activities through multi-dimensional data integration, supporting precision medicine, agricultural breeding, and environmental science.
Core user pain points addressed include: siloed omics data (genomics alone insufficient for disease understanding), lack of bioinformatics expertise, and high cost of in-house multi-omics infrastructure. Multi-omics services resolve these through integrated data analysis (cross-omics correlation), specialized bioinformatics pipelines, and outsourced scalability (pay-per-project).
Embedded Core Keywords (3–5)
- Multi-omics integration – genomics, proteomics, metabolomics
- Precision medicine – personalized treatment strategies
- Single-cell multi-omics – cellular resolution analysis
- Spatial multi-omics – tissue context preservation
- Bioinformatics pipeline – data processing and interpretation
1. Market Size and Growth (2025-2032)
| Year | Market Value (US$ million) | CAGR |
|---|---|---|
| 2025 | 564 | — |
| 2032 | 855 | 6.2% |
Growth drivers:
- Declining sequencing costs (NGS now <$500 per human genome)
- Precision medicine adoption (FDA批准的靶向疗法需要生物标志物)
- Single-cell and spatial technologies maturation
- Pharmaceutical R&D outsourcing (CROs offering multi-omics)
- Agricultural biotech (drought-resistant, high-yield crops)
Exclusive observation (Q1 2026): Single-cell multi-omics (scRNA-seq + scATAC-seq + surface protein) is fastest-growing segment (15%+ CAGR). Spatial multi-omics (preserving tissue architecture) emerging for肿瘤微环境研究.
2. Segment Analysis: Single-Cell vs. Spatial Multi-Omics
| Segment | Resolution | Tissue Context | Key Technologies | Applications | Market Share |
|---|---|---|---|---|---|
| Single-Cell Multi-omics | Cellular (individual cells) | Lost (dissociated cells) | scRNA-seq, scATAC-seq, CITE-seq (protein), scM&T (methylation + transcriptome) | 肿瘤异质性, 免疫细胞图谱, 发育生物学 | 50-55% (largest) |
| Spatial Multi-omics | Subcellular (tissue sections) | Preserved | Visium (10x Genomics), MERFISH, Xenium, CosMx | 肿瘤微环境, 神经科学, 组织病理学 | 20-25% (fastest growing) |
| Others (bulk) | Population average | Lost | Standard omics (RNA-seq, WGS, proteomics) | 经典研究, 农业育种 | 20-25% |
User case (2025, Cancer research – Single-cell multi-omics): A research institute used single-cell multi-omics (scRNA-seq + scATAC-seq) on tumor biopsies from 50 breast cancer patients. Identified rare cell subpopulation driving metastasis (0.5% of cells). Discovered novel therapeutic target (validated in mouse model). Published in Nature Cancer.
User case (2025, Immuno-oncology – Spatial multi-omics): A biotech company used spatial multi-omics (Visium + spatial proteomics) to map the tumor microenvironment before/after checkpoint inhibitor therapy. Identified spatial biomarkers predictive of response (PD-1/PD-L1 colocalization with CD8+ T cells). Biomarker panel filed for patent.
3. Applications by Industry
| Application | Description | Key Multi-Omics Layers | Market Share |
|---|---|---|---|
| Cancer Research | Tumor heterogeneity, metastasis mechanisms, biomarker discovery, drug resistance | Genomics + transcriptomics + proteomics + epigenetics | 35-40% (largest) |
| Rare Disease Diagnostics | Identify causal mutations (undiagnosed after exome) | Genomics + transcriptomics (RNA-seq for splicing) + proteomics | 10-15% |
| Drug Development | Target identification, pharmacodynamics, patient stratification | All layers (multi-omics) | 15-20% |
| Crop Breeding | Drought tolerance, yield improvement, disease resistance | Genomics + transcriptomics + metabolomics | 10-15% |
| Microbiome Research | Gut-brain axis, host-microbe interactions | Metagenomics + metatranscriptomics + metabolomics | 10-15% |
| Others | Neuroscience, aging, environmental science | Variable | 5-10% |
User case (2025, Rare disease – Multi-omics diagnosis): Undiagnosed pediatric patient (negative exome sequencing). Multi-omics service performed RNA-seq on muscle biopsy. Detected aberrant splicing of DMD gene (exon skipping). Confirmed by proteomics (absent dystrophin protein). Diagnosis: Becker muscular dystrophy (missed by exome). Patient received steroid therapy (improved outcomes).
User case (2025, Crop breeding – Multi-omics): An agricultural biotech company used multi-omics (genomics + transcriptomics + metabolomics) to screen 1,000 rice varieties for drought tolerance. Integrated analysis identified 12 candidate genes (validated in field trials). Developed drought-tolerant rice variety (20% yield increase under water stress).
4. Competitive Landscape
Key vendors: Metware (China), Genechem (China), Aptbiotech (US), Illumina (US, sequencing instruments, also services), BGI (China, global), Singleronbio (China, single-cell), Majorbio Group (China), Bioprofile (US), Dalton Bioanalytics (US), Source BioScience (UK), Psomagen (US), Biogenity (US), Sapient (US), Creative Biolabs (US), X-omics (US), RayBiotech (US), Sampled (US).
Market structure: Highly fragmented with many regional and specialty players. Illumina and BGI are largest (instrument + service). Singleronbio (single-cell), Metware (metabolomics), Majorbio (microbiome) are specialty leaders. Chinese vendors dominate domestic market (price advantage 40-50% below Western).
| Company | Region | Specialization | Key Advantage |
|---|---|---|---|
| Illumina | US/Global | Sequencing + multi-omics services | Technology leader, global reach |
| BGI | China/Global | Sequencing, multi-omics | Low cost, scale |
| Singleronbio | China | Single-cell multi-omics | Proprietary GEXSCOPE technology |
| Creative Biolabs | US | Custom multi-omics (pharma) | High-quality, regulatory support |
Exclusive insight (2026): Chinese multi-omics service providers (BGI, Metware, Genechem, Singleronbio, Majorbio) are expanding globally (Europe, North America) with pricing 40-50% below US/European competitors. Quality gap has narrowed (ISO 17025, CAP accredited). Western academic customers increasingly outsource to BGI for cost savings.
5. Technical Workflow and Bioinformatics
| Step | Description | Key Technologies | Typical Duration |
|---|---|---|---|
| Sample preparation | Tissue dissociation (single-cell), sectioning (spatial) | Microfluidics, cryostat | 1-2 days |
| Multi-omics data generation | Sequencing, mass spectrometry | NGS (Illumina), LC-MS | 2-5 days |
| Data preprocessing | QC, normalization, batch correction | FastQC, TrimGalore, Seurat | 1-2 days |
| Integration analysis | Cross-omics correlation, pathway analysis | MOFA, DIABLO, WGCNA | 2-5 days |
| Interpretation & reporting | Biological insights, figures, publication-ready | Custom (R, Python) | 2-5 days |
Technical bottleneck: Integration of heterogeneous omics data (scale mismatch: genomics ~30k genes, proteomics ~10k proteins, metabolomics ~1k metabolites). Computational methods (MOFA, DIABLO, WGCNA) require bioinformatics expertise. Interpretation requires domain knowledge (biology, pathology).
6. Forecast and Analyst Takeaways (2026–2032)
Growth projections: 6.2% CAGR. Single-cell multi-omics fastest-growing (12%+); spatial multi-omics emerging (8-10% after 2026). Asia-Pacific fastest region (8-10% CAGR) led by China.
| Region | 2025 Share | Key Drivers |
|---|---|---|
| North America | 40-45% | Research funding, pharma R&D |
| Europe | 25-30% | Precision medicine initiatives |
| Asia-Pacific | 20-25% | BGI, government funding, manufacturing |
Exclusive recommendations:
- For academic researchers: Outsource multi-omics to service providers (BGI, Creative Biolabs, Singleronbio) vs. building in-house (capital-intensive, requires bioinformatics staff). Single-cell requires expertise (cell viability >85%). Request raw data + analysis scripts (reproducibility).
- For pharma R&D (drug development): Multi-omics for target identification, patient stratification (clinical trials). Spatial multi-omics for tumor microenvironment in immuno-oncology. Choose CRO with regulatory expertise (FDA/EMA submission support, CAP/CLIA certified).
- For clinicians (rare disease): Multi-omics (especially RNA-seq) for undiagnosed cases (negative exome). RNA-seq identifies aberrant splicing (30% of missed diagnoses). Require multi-disciplinary interpretation (geneticist + bioinformatician).
- For procurement (cost-sensitive, China): Chinese multi-omics services (BGI, Metware, Genechem, Singleronbio) at 40-50% lower cost. Validate ISO/CAP accreditation, QC metrics (Q30 >85%, mapping rate >90%), and turnaround time (4-6 weeks).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
